Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer’s disease
Authors:
- Scott B. LaffoonSLScott B. Laffoon
- James D. DoeckeJDJames D. Doecke
- Anne M. RobertsARAnne M. Roberts
- Jennifer A. VanceJVJennifer A. Vance
- Benjamin D. ReevesBRBenjamin D. Reeves
- Kelly K. PertileKPKelly K. Pertile
- Rebecca L. RumbleRRRebecca L. Rumble
- Brett TrounsonBTBrett Trounson
- David AmesDADavid Ames
- Ralph MartinsRMRalph Martins
- Ashley I. BushAshley I. Bush
Open Access
- 26 January 2022
- journal article
- research article
- Published by Springer Nature in Proteome Science
- Vol. 20 (1) , 1-17
Abstract
Background: The Australian Imaging and Biomarker Lifestyle (AIBL) study of aging is designed to aid the discovery of biomarkers. The current study aimed to discover differentially expressed plasma proteins that could yield a blood-based screening tool for Alzheimer’s disease. Methods: The concentration of proteins in plasma covers a vast range of 12 orders of magnitude. Therefore, to search for medium to low abundant biomarkers and elucidate mechanisms of AD, we immuno-depleted the most abundant plasma proteins and pre-fractionated the remaining proteins by HPLC, prior to two-dimensional gel electrophoresis. The relative levels of approximately 3400 protein species resolved on the 2D gels were compared using in-gel differential analysis with spectrally resolved fluorescent protein detection dyes (Zdyes™). Here we report on analysis of pooled plasma samples from an initial screen of a sex-matched cohort of 72 probable AD patients and 72 healthy controls from the baseline time point of AIBL. Results: We report significant changes in variants of apolipoprotein E, haptoglobin, α1 anti-trypsin, inter-α trypsin inhibitor, histidine-rich glycoprotein, and a protein of unknown identity. α1 anti-trypsin and α1 anti-chymotrypsin demonstrated plasma concentrations that were dependent on APOE ε4 allele dose. Our analysis also identified an association with the level of Vitamin D binding protein fragments and complement factor I with sex. We then conducted a preliminary validation study, on unique individual samples compared to the discovery cohort, using a targeted LC-MS/MS assay on a subset of discovered biomarkers. We found that targets that displayed a high degree of isoform specific changes in the 2D gels were not changed in the targeted MS assay which reports on the total level of the biomarker. Conclusions: This demonstrates that further development of mass spectrometry assays is needed to capture the isoform complexity that exists in theses biological samples. However, this study indicates that a peripheral protein signature has potential to aid in the characterization of AD.Keywords
All Related Versions
Funding Information
- National Institutes of Health (5R42RR021790, 1P20RR024237)
- National Health and Medical Research Council (1164692, 1138673)
- Alzheimer's Drug Discovery Foundation
This publication has 97 references indexed in Scilit:
- Hepatic acute phase proteins – Regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signalingEuropean Journal of Cell Biology, 2012
- Plasma Biomarkers of Brain Atrophy in Alzheimer's DiseasePLOS ONE, 2011
- CSF biomarkers for Alzheimer's disease: current utility and potential future useNeurobiology of Aging, 2011
- Reduced Serum Vitamin D–Binding Protein Levels Are Associated With Type 1 DiabetesDiabetes, 2011
- Hemoglobin level in older persons and incident Alzheimer diseaseNeurology, 2011
- Alterations in the red blood cell membrane proteome in alzheimer's subjects reflect disease-related changes and provide insight into altered cell morphologyProteome Science, 2010
- Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s diseaseBiomarkers, 2009
- In-gel digestion for mass spectrometric characterization of proteins and proteomesNature Protocols, 2006
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003
- Identification of oxidized plasma proteins in Alzheimer's diseaseBiochemical and Biophysical Research Communications, 2002